Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214

Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214

Source: 
BioCentury
snippet: 

Pfizer Inc. (NYSE:PFE) will combine NKTR-214 from Nektar Therapeutics Inc. (NASDAQ:NKTR) with the pharma's marketed drugs Xtandi enzalutamide, Talzenna talazoparib and Bavencio avelumab to treat prostate cancer, testing the biotech's hypothesis that stimulation of IL-2 alongside these other MOAs in tumors with a high mutational burden could provide synergistic benefits.